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Hypertension is particularly prevalent in patients aged
X65 years, those with a body mass index X30kgm
 2,
Blacks and those with type II diabetes. Here we report a
prespecified secondary analysis of the efficacy of
amlodipine (10mgday
 1), olmesartan medoxomil
(40mgday
 1), a combination of the two and placebo in
these subgroups. Patients were randomized to treat-
ment for 8 weeks. The primary efficacy endpoint was the
change from baseline in mean seated diastolic blood
pressure (DBP). Secondary efficacy endpoints included
the change from baseline in mean seated systolic
BP (SBP), proportions of patients achieving BP goal
(o140/90mmHg or o130/80mmHg in patients with
diabetes), and the number and percentage of patients
achieving a range of BP targets. Safety and tolerability
of amlodipine 5 and 10mg, olmesartan medoxomil 10,
20 and 40mg, and all possible combinations of the
two were also assessed. For each prespecified sub-
group, all active treatments resulted in significant BP
reductions from baseline (Po0.05). The antihyperten-
sive effect of the combination of amlodipineþ
olmesartan medoxomil was generally greater than the
constituent amlodipine or olmesartan medoxomil mono-
therapies, regardless of subgroup. In general, more
patients receiving combination therapy achieved BP
goal than those treated with monotherapies. The safety
and tolerability of combinations were similar to
monotherapies across the subgroups. These results
suggest that the combination of amlodipineþ
olmesartan medoxomil provides a safe and effective
option for the treatment of hypertension in challenging
patient populations.
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Introduction
It is well established that effective blood pressure
(BP) control reduces the risk of cardiovascular
disease and stroke in patients with hypertension.
1,2
For every 20mmHg decrease in systolic BP (SBP),
there are 30 and 40% reductions in ischaemic heart
disease and stroke mortality, respectively.
3
However, only a small proportion of patients
achieve BP goal (o140/90mmHg or o130/
80mmHg in patients with diabetes) with antihyper-
tensive monotherapy.
1,2 The Seventh report of the
Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure
(JNC 7) and the European Societies of Hypertension
and Cardiology guidelines recognize that in the
majority of patients, combination therapy will be
required.
1,2
The prevalence of hypertension (BP X140/
90mmHg or X130/80mmHg in patients with
diabetes) is approximately 33% in the general
population and even higher in certain patient
populations.
4,5 In the elderly, 63.6% of women and
73.9% of men have hypertension.
4,5 Hypertension
prevalence is also higher in Blacks (41.4%), patients
with diabetes (76.8%) and those who are obese
(body mass index (BMI) X30kgm
 2; 40.8%).
5–8 In
the case of elderly or patients with diabetes, this is
due, in part, to arterial stiffness as a consequence of
the pathobiology of ageing or diabetes.
9,10 Causes of
the increased prevalence of hypertension in Blacks
have not been fully elucidated, though it appears
that physiological factors may have a part.
11 In
addition, Black children have significantly higher
BP than age-matched Caucasian children of o10
years of age, and Blacks with hypertension generally
present with more severe disease.
4,5 In obese
patients, the renin–angiotensin system may be
dysregulated contributing to the development of
hypertension.
12
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www.nature.com/jhhTreating hypertension in patients with diabetes is
challenging because of a stringent BP goal (o130/
80mmHg) that has been shown to reduce the
progression of diabetic nephropathy onto end-stage
renal disease and other complications of dia-
betes.
1,2,13 Treatment guidelines from scientific com-
mittees recommend the use of two or more
antihypertensive agents for control of BP in Blacks
or patients with diabetes, and generally recommend
the use of two or more antihypertensive agents if BP
is X20/10mmHg above goal in any patient.
1,2,13
Combinations of angiotensin receptor blockers
(ARBs) and calcium channel blockers (CCBs) are
recognized by the European Society of Hypertension
and the European Society of Cardiology as effective
and well-tolerated therapeutic options.
2 It has been
shown that combination therapy with an ARB or an
angiotensin-converting enzyme inhibitor with a CCB
may minimize the adverse effects of the CCB, such
as peripheral oedema.
14,15 ARBs also provide protec-
tion against renal and cardiac end-organ failure,
16
which is of particular importance in patients with
diabetes and hypertension. A recent long-term
clinical outcomes study, ACCOMPLISH (Avoiding
Cardiovascular Events in Combination Therapy in
Patients Living With Systolic Hypertension), has
shown that the combination of renin–angiotensin
system blockade (angiotensin-converting enzyme
inhibitor—benazepril) with a CCB (amlodipine)
was more effective in reducing cardiovascular
complications than the combination of renin–angio-
tensin system blockade (benazepril) with a diuretic
(hydrochlorothiazide).
17,18
The results of the COACH (Combination of
Olmesartan Medoxomil and Amlodipine Besylate
in Controlling High Blood Pressure) study, a clinical
trial that assessed the efficacy and safety of
amlodipine besylate (dihydropyridine CCB) in com-
bination with olmesartan medoxomil (ARB) in
patients with mild-to-severe hypertension, have
been published elsewhere.
19 Here we report a
prespecified subgroup analysis of the COACH study
in patients with diabetes, Blacks, elderly (X65
years) patients and those who are overweight/obese
with a BMIX30kgm
 2.
Materials and methods
Study population
This was an 8-week multicenter, randomized,
double-blind, factorial design study conducted at
172 sites in the United States of America. Inclusion
criteria have been described in detail elsewhere.
19
Briefly, patients who were aged X18 years with both
a mean seated diastolic BP (SeDBP) of 95–
120mmHg from 1 week before randomization and
at the randomization visit with a mean SeDBP
difference of p10mmHg from the two separate
visits were randomized to treatment. Subgroup
analyses were carried out for each of the following
variables: diabetes status (yes/no), age (o65 years
and X65 years) and baseline BMI (X30kgm
 2,
o30kgm
 2). A further subgroup analysis was made
on the basis of race (Black/non-Black).
Patients with a history of cardiovascular disease,
SeDBP4120mmHg, uncontrolled diabetes (glyco-
sylated haemoglobin (HbA1c) 49.0%), history of
drug or alcohol abuse, those who smoked 41 pack
of cigarettes per day, and those with any medical
condition judged by investigators to possibly jeo-
pardize the evaluation of efficacy and safety of
therapy were excluded from the study. Patients were
also excluded for whom participation in the study
constituted a significant risk.
The study was conducted in accordance with
the institutional review board committee regula-
tions and the Declaration of Helsinki. Written
informed consent was obtained from each patient
at screening.
Study design
Patients who are currently not taking any antihy-
pertensive medications (for example, naı ¨ve) or those
who have completed a washout of their current
antihypertensive medications and who have met BP
enrollment criteria were randomized to 1 of the 12
treatment regimens: placebo, amlodipine monother-
apy (5 or 10mgday
 1), olmesartan medoxomil
monotherapy (10, 20 or 40mgday
 1) or combination
therapy with amlodipineþolmesartan medoxomil,
including all possible dose combinations of the
monotherapy groups.
19 Randomization included a
stratification based on age (o65 years and X65
years) and diabetes status. Efficacy data reported
here comprise the highest US Food and Drug
Administration-approved dosage of amlodipine
(10mgday
 1) combined with olmesartan medoxomil
(40mgday
 1), the constituent monotherapies and
placebo. Efficacy data are not reported for patients
receiving olmesartan medoxomil 10mgday
 1,
20mgday
 1, amlodipine 5mgday
 1, amlodipineþ
olmesartan medoxomil 5þ10mgday
 1,5 þ
20mgday
 1,5 þ40mgday
 1,1 0 þ10mgday
 1 and
10þ20mgday
 1 but are available in Supplementary
Tables 1 and 2.
Patients were instructed to take their medication
at the same time each day (±2h). Clinic visits were
scheduled to allow a trough BP measurement 24h
after the normal dosing time, and patients were
refrained from taking their daily medication until all
the measurements were completed.
Therapeutic efficacy and safety were evaluated at
weeks 2, 4, 6 and 8. Vital signs, including BP and
heart rate, were obtained at all scheduled visits. BP
was assessed at all participating sites using an
automated BP-monitoring device (Omron Model
HEM-705CP). After a 5-min rest period, three
separate seated BP (SeBP) measurements were taken
at 1min apart, and the mean of the three readings
was recorded.
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population was the primary-analysis population
and included all the patients who took at least one
dose of double-blind study medication and had one
post-baseline BP measurement. Patients who took at
least one dose of randomized, double-blind study
medication were included in the safety population.
Efficacy variables
The primary efficacy variable was the change from
baseline in mean SeDBP at week 8, using the last
observation carried forward (LOCF) for patients who
did not complete the study protocol (week 8/LOCF).
The secondary efficacy variable was the change from
baseline in mean SeSBP at week 8/LOCF. Other
efficacy variables assessed included the following:
change from baseline in mean SeDBP and mean
SeSBP at weeks 2, 4, 6 and 8 without LOCF;
proportion of patients achieving BP goal (combined
term of o140/90mmHg or o130/80mmHg for
patients with diabetes) at weeks 2, 4, 6, 8 and
8/LOCF; proportion of patients achieving BP
targets at week 8/LOCF (o140/90mmHg and o120/
80mmHg); and comparison of reductions in mean
SeSBP and mean SeDBP between combination
therapy and its constituent monotherapy compo-
nents. These efficacy assessments were also applied
to prespecified subgroups including age (o65 years,
X65 years), race (Black and non-Black), diabetes
status and baseline BMI (o30kgm
 2 and
X30kgm
 2).
Safety variables
Adverse events (AEs) and serious AEs were re-
corded at all visits. This study used the definition of
a serious AE provided by the US Food and Drug
Administration. The occurrence and severity of
peripheral oedema were proactively assessed at all
scheduled clinic visits, and when oedema was
present, the severity was rated on a 5-point scale
based on the following categories: no oedema; mild
pitting, slight indentation; moderate pitting or
indentation; deep pitting, indentation remains; and
leg remains swollen. Investigators were encouraged
to report increases in the severity of oedema as AEs.
Safety data are presented for all monotherapies,
drug combinations and placebo.
Statistical analysis
Summary statistics were determined for baseline,
endpoint, and the mean change in SeDBP and
SeSBP at week 8/LOCF for each level of the
subgroup variables. One-sided P-values for testing
the significance of combination therapy versus each
monotherapy component were derived from an
analysis of covariance model that used treatment
group, subgroup and treatment-by-subgroup inter-
action as fixed effects and study baseline BP as a
covariate. As P-values were one-sided for this
comparison, differences between combination thera-
pies and monotherapy components were significant
if Po0.025. Though the analyses were prespecified,
the study was only powered to show statistical
differences between combination therapy and its
constituent monotherapy components in the overall
study cohort and was not powered to show
statistical significance within the treatment regi-
mens in each of the prespecified subgroups.
All SeSBP and SeDBP reductions are reported
here as least-squares means. Least-squares means,
corresponding standard errors, and 95% two-sided
confidence intervals, as well as the difference in
least-squares means, corresponding standard error,
and 95% two-sided confidence intervals, were also
derived from this analysis of covariance model. A
w
2-test was employed to determine the significance of
differences between treatment groups for the number
of patients reaching BP goal. One-sided P-values
were obtained from individual Fisher’s exact tests.
Results
A total of 4234 patients were screened, 1940 patients
were randomized and 1689 completed the 8-week
double-blind portion of the study.
19 The mean age
for the study cohort was 54.0 years, 19.8% were X65
years, 54.3% were male and 24.8% were Black. The
mean baseline BMI was 33.5kgm
 2, 64.7% of
patients were classified as obese (BMIX30kgm
 2)
and patients with diabetes comprised 13.5% of the
total study population. The overall mean baseline
SeBP was 163.8/101.6mmHg. The baseline demo-
graphics for each subgroup are presented in Table 1.
For each subgroup analysed, by week 8/LOCF,
SeDBP and SeSBP were significantly reduced from
baseline for all olmesartan medoxomil monotherapy
(Po0.05), amlodipine monotherapy (Po0.0001) and
amlodipineþolmesartan medoxomil (Po0.0001) treat-
ment regimens. Generally, the greatest reduction from
baseline occurred in patients receiving amlodipineþ
olmesartan medoxomil 10þ40mgday
 1. These
efficacy data for each subgroup and the compa-
risons with amlodipine 10mgday
 1, olmesartan
medoxomil 40mgday
 1 and placebo are presented
(Figure 1).
Age
At week 8/LOCF, changes in mean SeBP were
 29.1/ 18.5 and  33.9/ 20.9mmHg for patients
aged o65 years and X65 years, respectively, who
received amlodipineþolmesartan medoxomil
10þ40mgday
 1 (Figure 1). All SeBP changes were
significant for combination therapy compared with
the monotherapy components with the exception of
the reduction in mean SeSBP in patients aged X65
years versus amlodipine. The combined BP goal of
o140/90mmHg, and o130/80mmHg for those
Efficacy of amlodipineþolmesartan medoxomil
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aged o65 years (Figure 2). In patients aged X65
years, this goal was achieved by fewer patients
(21.2%) who received combination therapy com-
pared with amlodipine monotherapy (31.1%) des-
pite the greater SeBP reductions observed. This
discrepancy may be because of the lower number
of patients in this subgroup. For example, 43.8% of
patients aged X65 years who received the amlodipi-
neþolmesartan medoxomil 10þ20mgday
 1 regimen
achieved BP goal (data not shown). Achievement of
the prespecified BP targets of o140/90, o130/80 and
o120/80mmHg was also measured cumulatively
through the duration of the study. These targets were
achieved at the highest rates in patients who received
amlodipineþolmesartan medoxomil combinations
that included amlodipine 10mgday
 1, regardless of
age. (Supplementary Table 2).
Race
At week 8/LOCF, changes in mean SeBP were
 28.7/ 15.7 and  30.5/ 19.9mmHg for Black and
non-Black patients, respectively, who received am-
lodipineþolmesartan medoxomil 10þ40mgday
 1
(Figure 1). At this dosage, the SeBP changes were
significant for combination therapy compared
with the monotherapy components for non-Black
patients and for Black patients with olmesartan
medoxomil but not with amlodipine monotherapy.
In non-Black patients, BP goal was achieved by
52.0% of those who received combination therapy, a
greater proportion than observed for the monother-
apy groups (Figure 2). More Black patients who
received amlodipine 10mgday
 1 (43.6%) achieved
the BP goal compared with combination therapy
comprising amlodipineþolmesartan medoxomil
10þ40mgday
 1 (38.2%), although this may also
be because of the lower number of patients in this
subgroup. For example, 45.7% of Black patients
who received the amlodipineþolmesartan medox-
omil 10þ20mgday
 1 regimen achieved BP goal
(data not shown). Regardless of race, combination
therapies enabled more patients to achieve the
prespecified BP targets of o140/90, o130/80 and
o120/80mmHg compared with monotherapy
(Supplementary Table 2).
Diabetes status
In patients with and without diabetes similar
changes in mean SeBP from baseline were observed.
At week 8/LOCF, changes in mean SeBP were
 30.3/ 18.4 and  30.1/ 19.1mmHg for patients
with and without diabetes, respectively, who
received amlodipineþolmesartan medoxomil
10þ40mgday
 1 (Figure 1). All SeBP changes were
significant for combination therapy compared with
the monotherapy components. In patients without
diabetes, 55.5% achieved BP goal (o140/90mmHg)
at week 8/LOCF when treated with combination
therapy (Figure 2).The more stringent BP goal of
o130/80mmHg was achieved by 12.5% of patients
with diabetes who received combination therapy.
Achievement of the prespecified BP targets of o140/
90, o130/80 and o120/80mmHg are shown in
Supplementary Table 2.
Baseline BMI
In both BMI subgroups, patients who received
amlodipineþolmesartan medoxomil combination
Table 1 Baseline patient demographics according to subgroup (intent-to-treat population)
Age Race Diabetes status BMI
o65 years
(n¼1541)
X65 years
(n¼382)
Black
(n¼474)
Non-Black
(n¼1449)
Diabetes
(n¼258)
No diabetes
(n¼1665)
o30kgm
 2
(n¼658)
X30kgm
 2
(n¼1251)
Mean age, years±s.d. 50.2±8.5 69.8±3.3 50.8±10.8 55.1±11.0 57.0±10.7 53.6±11.1 56.4±11.1 52.8±10.9
AgedX65 years, n (%) NA 382 (100%) 62 (13.1%) 320 (22.1%) 73 (28.3%) 309 (18.6%) 179 (27.2%) 199 (15.9%)
Males, n (%) 836 (54.3%) 209 (54.7%) 191 (40.3%) 854 (58.9%) 151 (58.5%) 894 (53.7%) 385 (58.5%) 649 (51.9%)
Hispanic or Latino,
n (%)
195 (12.7%) 46 (12.0%) 15 (3.2%) 226 (15.6%) 54 (20.9%) 187 (11.2%) 88 (13.4%) 151 (12.1%)
Black, n (%) 412 (26.7%) 62 (16.2%) 474 (100%) NA 66 (25.6%) 408 (24.5%) 143 (21.7%) 328 (26.2%)
Diabetes, n (%) 185 (12.0%) 73 (19.1%) 66 (13.9%) 192 (13.3%) 258 (100%) NA 57 (8.7%) 199 (15.9%)
Previous antihyper-
tensive therapy, n (%)
962 (62.4%) 304 (79.6%) 324 (68.4%) 942 (65.0%) 191 (74.0%) 1075 (64.6%) 445 (67.6%) 812 (64.9%)
Oedema present, n (%) 199 (12.9%) 64 (16.8%) 75 (15.9%) 188 (13.0%) 51 (19.8%) 212 (12.7%) 38 (5.8%) 224 (17.9%)
Mean BMI, kgm
 2±s.d. 33.9±7.2 31.6±6.4 34.6±7.9 33.1±6.8 35.2±6.8 33.2±7.1 26.7±2.6 37.0±6.0
BMIX30kgm
 2, n (%) 1052 (68.3%) 199 (52.1%) 328 (69.2%) 923 (63.7%) 199 (77.1%) 1052 (63.2%) NA 1251 (100%)
Baseline BP
Mean SeSBP, mmHg±s.d. 161.4±14.8 173.6±17.4 163.9±16.6 163.8±15.9 168.6±16.6 163.1±15.9 165.1±16.0 163.1±16.0
Mean SeDBP, mmHg±s.d. 102.0±5.2 100.3±4.5 102.4±5.4 101.4±5.0 101.1±5.1 101.7±5.2 100.8±4.7 102.1±5.3
Abbreviations: BMI, body mass index; BP, blood pressure; NA, not applicable; s.d., standard deviation; SeDBP, seated diastolic BP; SeSBP, seated
systolic BP.
Total n for each subgroup and data reported reflect all 12 treatment arms.
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SeDBP and SeSBP than their component mono-
therapies (Figure 1). At Week 8/LOCF, changes in
mean SeBP were  30.6/ 20.6 and  29.7/
 17.9mmHg for patients with BMI o30kgm
 2
and X30kgm
 2, respectively, who received amlodi-
pineþolmesartan medoxomil 10þ40mgday
 1
(Figure 1). The BP goal was achieved by similar
proportions of patients in each BMI subgroup. For
patients treated with combination therapy, 53.3% of
patients with baseline BMI o30kgm
 2 and 46.0%
with baseline BMIX30kgm
 2 achieved BP goal
(Figure 2). There was a trend for more patients with
a baseline BMI o30kgm
 2 to achieve BP targets of
o120/80 and o130/80mmHg compared with pa-
tients with a baseline BMIX30kgm
 2 (Supplemen-
tary Table 2).
Safety
When comparing the safety profile obtained in those
patients aged X65 years or o65 years, Black or non-
Blacks, those with or without diabetes, or in patients
with a BMIX30kgm
 2 or o30kgm
 2, no marked
differences were observed. There was one serious
AE (cerebrovascular accident) considered to be
drug-related, occurring in a Black, obese female
patient aged o65 years with type II diabetes in the
olmesartan medoxomil 20mgday
 1 group. Safety
data are reported categorically for all the 12 treat-
ment groups who received placebo, amlodipine
monotherapy, olmesartan medoxomil monotherapy
and amlodipineþolmesartan medoxomil combina-
tion therapy (Table 2).
Age. Among patients aged X65 years, 7.0% (27 out
of 384) discontinued from the study because of
treatment-emergent AEs (TEAEs), 4.2% (16 out of
Figure 1 Mean reductions in SeSBP and SeDBP from baseline to
week 8/LOCF according to subgroup and treatment regimen.
(a) Age subgroups; (b) race subgroups; (c) diabetes subgroups; and
(d) baseline BMI subgroups. AML, amlodipine; LOCF, last
observation carried forward; PL: placebo; A10: amlodipine
10mg; OM40: olmesartan medoxomil 40mg; and Aþ01 0 þ40:
amlodipineþolmesartan 10þ40mg. Statistics for comparisons to
baseline are two-sided. n represents number of patients who
received indicated treatment. Po0.0001 versus baseline for each
SeBP change from baseline unless otherwise noted. *Po0.01
versus baseline;
wNot significant versus baseline;
zPo0.001 versus
baseline;
yPo0.05 versus baseline. Statistics for combinations
versus monotherapy components used least-squares mean de-
rived from an analysis of covariance model with treatment,
subgroup and treatment-by-subgroup interaction as fixed effects
and baseline BP as covariate and are one-sided. Symbol for
comparison with olmesartan medoxomil monotherapy precedes
symbol for comparison with AML monotherapy component.
aPo0.0001 versus both monotherapy components;
bPo0.01
versus olmesartan medoxomil monotherapy component;
cPo
0.0001 versus olmesartan medoxomil monotherapy component;
dPo0.025 versus AML monotherapy component;
ePo0.01 versus
AML monotherapy component;
fPo0.001 versus AML mono-
therapy component;
gNot significant versus AML component.
Bars represent standard errors of the mean.
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patients o65 years of age, 5.3% (82 out of 1556)
discontinued because of TEAEs, 3.7% (58 out of
1556) of which were considered drug related. The
number and proportion of specific drug-related
TEAEs associated with CCB and/or ARB antihyper-
tensive medications are summarized in Table 2.
Rates of hypotension were similar in both sub-
groups.
Race. Twenty-one Black patients (4.4%) discon-
tinued due to TEAEs, 13 (2.7%) of which were
considered drug-related. In non-Black patients, 88
(6.0%) discontinued due to TEAEs, 61 (4.2%) of
which were considered to be drug-related. The
number and proportion of specific TEAEs associated
with CCB and/or ARB antihypertensive medications
are summarized in Table 2. The incidence of oedema
was lower in non-Black patients that received
combination therapy, compared with amlodipine
monotherapy. However, as with the total study
cohort
19 oedema was lower in patients with dia-
betes who received amlodipine+olmesartan medo-
xomil 10+40mgday
 1 compared with amlodipine
10mgday
 1 monotherapy (data not shown).
Diabetes status. Among patients with diabetes, 12
(4.6%) discontinued because of TEAEs, 9 (3.4%) of
which were considered to be drug related. Among
patients without diabetes, 97 (5.8%) discontinued
because of TEAEs and 65 (3.9%) were considered to
be drug related. The number and proportion of
specific TEAEs associated with CCB and/or ARB
antihypertensive medications are summarized in
Table 2. In general, patients with diabetes who
received combination therapy had slightly higher
incidences of oedema compared with respective
monotherapies.
Baseline BMI. In patients with a baseline
BMIX30kgm
 2, 72 (5.7%) discontinued because of
TEAEs and 54 (4.3%) were considered to be drug
related. In patients with a BMI o30kgm
 2, 37 and
20 (5.5 and 3.0%) discontinued because of TEAEs
and drug-related TEAEs, respectively. The number
and proportion of specific TEAEs associated with
CCB and/or ARB antihypertensive medications are
summarized in Table 2.
Discussion
Achieving target BP is a continuing challenge for the
management of patients with hypertension. As such,
it is acknowledged that the majority of patients,
especially those with multiple risk factors, will
require combination therapy with at least two
antihypertensive agents to achieve optimal BP con-
trol.
1,2 Nevertheless, evidence indicates that patients
are often not treated to their target BP goal.
7,20 The
combination of amlodipineþolmesartan medoxomil
Figure 2 Proportion of patients reaching BP treatment goal (o140/
90mmHg or o130/80mmHg for patients with diabetes) by week 8/
LOCF according to subgroup and treatment regimen. (a)A g e
subgroups; (b)r a c es u b g r o u p s ;( c) diabetes subgroups; and (d) baseline
BMI subgroups. AML, amlodipine; BMI, body mass index; LOCF, last
observation carried forward; and OM, olmesartan medoxomil.
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Journal of Human Hypertensionlowers BP through different but complementary
mechanisms of action. This results in additive BP-
lowering effects through multiple inhibitory mechan-
isms, complementing the efficacy of the other
antihypertensive agent and may offer wider benefits
over and above BP control.
14,15
In this study, there was a consistent dose-response
effect across a range of prespecified patient groups,
analysed according to age, race, diabetes status and
BMI. Across all subgroups, high doses of amlodipi-
neþolmesartan medoxomil combinations produced
greater reductions in BP than either of the mono-
therapy components, allowing a greater proportion
of these perceived difficult-to-treat patients to
achieve the target BP goal. For the primary endpoint,
amlodipineþolmesartan medoxomil 10þ40mg
day
 1 produced the greatest reductions in mean
SeDBP at week 8/LOCF in all subgroups. However,
unlike the overall cohort, it should be noted that this
study was not powered to show statistical differences
between combination therapy and its component
monotherapies within the subgroups.
Age did not appear to affect the magnitude of
SeDBP reduction, and there were generally greater
reductions in patients that received combination
therapy compared with monotherapy. Numerically
greater reductions in SeSBP were seen in patients
X65 years of age compared with those aged o65
years. However, the 10mmHg higher baseline
SeSBP in patients aged X65 years likely contributed
to the lower proportions of these patients achieving
the recommended BP goal of o140/90mmHg or
o130/80mmHg in patients with diabetes.
Black patients tended to have higher baseline BP
than the non-Black patients. When treated with
olmesartan medoxomil monotherapy, Blacks had nu-
merically lower reductions in mean SeDBP and SeSBP
compared with non-Blacks. However, the addition of
amlodipine in the combination treatment groups
provided comparable BP reductions in Blacks and
non-Blacks. Greater reductions were seen with amlo-
dipineþolmesartan medoxomil 10þ40mgday
 1,
where mean BP reductions reached approximately
29/16mmHg in the Black subgroup and 31/20mmHg
in non-Black patients. In both race subgroups, more
patients on combination therapy achieved their BP goal
compared with patients on monotherapy.
Similar overall reductions in mean SeDBP and
SeSBP were observed in patients with and without
diabetes. However, the lower BP goal of o130/
80mmHg and the higher baseline BP resulted in
fewer patients with diabetes achieving the BP goal,
compared with patients without diabetes who had a
less stringent goal (BPo140/90mmHg). These re-
sults support the assertion that patients with
diabetes are likely to require 42 antihypertensive
drugs to achieve the BP goals recommended by the
American Diabetes Association.
6,13
Similar overall mean SeBP reductions from base-
line were also observed in patients irrespective of
baseline BMI. Generally, more patients achieved BP
goal when administered combination therapy of
amlodipineþolmesartan medoxomil compared
with either drug as monotherapy. The incidence of
oedema was greater in patients with a baseline
BMI430kgm
 2. This may have been due, in part, to
obesity confounding the diagnosis of oedema.
Overall, combinations of amlodipineþolmesartan
medoxomil generally produced greater BP reductions
than component monotherapies regardless of age, race,
diabetes status or BMI. The amlodipineþolmesartan
medoxomil 10þ40mgday
 1 combination produced
the greatest reductions in mean SeDBP in all sub-
groups and in SeSBP in all subgroups except non-
Blacks. In non-Blacks, the greatest reduction in mean
SeSBP was produced by amlodipineþolmesartan
medoxomil 10þ20mgday
 1 (data not shown). In
addition, safety and tolerability profiles were similar
when comparing subgroups with difficult-to-treat
hypertension with their counterparts with more easily
treated disease as well as for the monotherapy-treated
cohorts. In these subgroups, as with the total study
cohort,
19 oedema was higher in patients who received
amlodipine 10 mg day
 1 monotherapy compared with
amlodipine + olmesartan medoxomil 10 + 40 mg day
 1
(data not shown). A fixed-dose combination of
amlodipineþolmesartan medoxomil has been ap-
proved by the US Food and Drug Administration as
initial therapy for patients with hypertension unlikely
to reach BP goal on monotherapy and may provide
more flexibility for the successful treatment of hard-to-
treat hypertensive patients.
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